Status:
UNKNOWN
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
Lead Sponsor:
University of Aarhus
Conditions:
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Eligibility:
All Genders
18-100 years
Brief Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or abs...
Detailed Description
Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Ofte...
Eligibility Criteria
Inclusion
- Patients diagnosed with CIDP or MMN or patients suspected to have CIDP or MMN
- Controls:
- Age \>18 years
Exclusion
- \<18 years
- Acute infections including neuroinfection
- Diabetes
- Other disorders known to have elevated levels of sCD163 and CD19
- Disorders or treatments that contraindicate a lumbar puncture.
Key Trial Info
Start Date :
September 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2016
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT02271724
Start Date
September 1 2015
End Date
November 1 2016
Last Update
May 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, Aarhus University Hospital
Aarhus C, Denmark, 8000